# DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

> **NCT05755360** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 291 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT05755360
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-21
- **Primary completion:** 2024-10-21
- **Final completion:** 2024-10-21
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755360, "DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05755360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*